The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Phantom - all I was pointing out was that the specific numbers Jelenko quoted in his earlier post were wrong.
I made no reference to profit or loss.
Jelenko I think if you go back and read my post I was confirming your statement that EXAS is a loss maker unlike Hmmm who was suggesting otherwise
Phantom I think we all know that revenue is for vanity and profit is for sanity and also that EXAS are not making profit BUT the
Americans don't seem to care about profit so I think it is fair to compare on a revenue basis. Normally I would work PE's on profit also but in this case you have to have a different approach.
AN does come across as the consumate professional ,on screen he eminates kudos .
in his hands we are safe
No idea O&W,
But you know AN. Everything planned meticulously! Not suggesting we should totally trust anyone but he does seem to be exceptional.
ATB
So when will AGL be getting a NASDAQ listing and putting its valuation on a par with its US peer group of companies?
EXAS
Revenue is not profit!
Profit for year end 2020 was negative, or a loss of $850 mln
I just looked at Exas - Mcap is $22bn not £ and latest reported revenue is $1.5bn which I calculate as about 15 x sales.
It’s interesting enough without the exaggeration....
Miavoce.
Both thermo and abbott make roughly 7 billion dollars a year profit.
With that kind of money they could buy angle for 5+ billion relatively easy.
AN just needs to keep doing his thing and that's what the future could hold
Th kind of Pharma that would buy AGL would be one that has a significant focus on diagnostics such as Abbott or Thermo Fisher. Given then the potential profit that Parsortix could generate for them they will be keen to acquire AGL IMO.
A large pharma wouldn't be buying Parsortix for in house use only, it would be for future profits from the product.
Large pharma Co's are forced to buy minnows if they make substantial profit. There is nothing gained by putting the cash in the bank.
can't see the reason for a large pharma to buy AGL, as A.N. said in the interview they outsource their drug trial analysis anyway.
If anyone it will be a large player already in the Liquid biopsy space. and that could spark a biding war.
Turning Angle into a global giant will be AN's life's work from now on - no way IMO will he be taking his eye off that ball (unless a major pharma swoops in with an offer that can't be refused).
Another thing to consider is that when income starts to roll in A.N. will be looking for more early stage technology under the radar to buy. A lot of new investors probably don't realise that AGL didn't invent Parsortix, they bought it. Likewise the graphics rendering software that eventually got sold to ARM
Phantom, EXAS, a lab based company in the U.S that AGL have used as a comparison are on a sales multiple of 25 times!
Still not making a profit, mkt cap £22b!!!
Going back to that 30 March RNS. Apart from the flagging up of number of conversations with clients we also had this separate comment in regard to the “white label” use of Parsortix.
“As well as working with pharmaceutical company customers directly, we are keen to work with contract research organisations both as a white label service and, when they wish to deploy the tests internally, by supplying Parsortix systems so that they can directly offer their own CTC services for cancer drug trials. This will enable us to scale the commercial use of the Parsortix system in this large market. We are in advanced discussions with potential customers and we look forward to updating the market on the first contracts in due course."
Some will argue that current mkt cap is high enough atm. They clearly don’t get it. Just watch that video again. They can’t fully calculate the size of the market they are addressing. Just one subsection is worth $1.2b and AGL are the only company who can address that.
This feels like one of those shares that in 12m time you ask yourself why didn’t I buy more?
So using those figures and PE ratio of 20
AGL mkt cap would be 1 to 2 billion SP 4 to £8
All Without FDA approval.
PE of 20 is very conservative. Abbott has a PE of 50
This is of course ignoring cost of sales, but we know they are low, as a cassette only costs £10
Would also have to add lab costs. But it is obvious that we will not get bought for £4
I thought his comment about current lab capacity interesting, 25,000 tests per year at each lab. so 50,000 tests and a price of between $1000 and $2000 per test. So at that we have a lab sales revenue capacity of between $50-$100m per year.
That's now not pie in the sky stuff. I think 99p a tad low.
'a number of these conversations' certainly sound like, well, more than three shall we say?, at the time AN said it.